Laurent Pharmaceuticals Receives Approval from FDA to initiate its COVID-19 Phase 2 Clinical Trial

The Phase 2 study aims to evaluate the dual antiviral and inflammation-controlling effects of the company’s LAU-7b oral drug candidate against COVID-19 infection

Read More

Committed to developing treatments
for severe inflammatory
and fibrotic diseases

Events

Laurent Pharmaceuticals to participate at NACFC 2019, in Nashville TN, October 31st - November 2nd 2019

Laurent Pharmaceuticals to participate at  BIO2019, in Philadelphia PA, June 3-6 2019

 

News

Laurent Pharmaceuticals Receives Approval from FDA to initiate its COVID-19 Phase 2 Clinical Trial in the United States

Read more  

Laurent Pharmaceuticals Joins Battle Against COVID-19

Read more